Trastuzumab use in breast cancer: clinical issues
1Interdisciplinary Oncology Program at the University of South Florida, Tampa, USA. horton@moffitt.usf.edu
Background:
Overexpression of the epidermal growth factor 2 HER2 in breast cancer tissue is associated with shorter survival. Trastuzumab, a monoclonal antibody against HER2, can induce tumor responses when given alone and enhances the effectiveness of several chemotherapeutic agents.
Methods:
The recent clinical data on outcomes regarding testing for HER2 overexpression and the tolerance, toxicity, and antitumor effects of trastuzumab are reviewed.
Results:
Trastuzumab use is indicated either alone or with chemotherapy only in patients with IHC 3+ or FISH+ test results and survival is prolonged in patients with metastatic disease. Cardiac toxicity differs from anthracycline cardiac toxicity and is often reversible.
Conclusions:
The safety and efficacy profile of trastuzumab in patients with metastatic disease has led to large-scale testing of addition of the intervention in the adjuvant setting.
Insights
Trastuzumab is an effective treatment for HER2-positive breast cancer, improving survival in metastatic cases. This antibody therapy shows manageable cardiac toxicity and is being explored for adjuvant use.
Area of Science:
- Oncology
- Immunotherapy
- Breast Cancer Research
Background:
- HER2 overexpression in breast cancer correlates with poorer patient survival.
- Trastuzumab, an anti-HER2 monoclonal antibody, demonstrates antitumor activity and enhances chemotherapy efficacy.
Purpose of the Study:
- To review clinical data on HER2 testing, trastuzumab tolerance, toxicity, and efficacy.
- To evaluate trastuzumab's role in metastatic and adjuvant breast cancer settings.
Main Methods:
- Review of recent clinical data and outcomes.
- Analysis of testing methods for HER2 overexpression (IHC 3+, FISH+).
- Assessment of trastuzumab's safety, toxicity, and antitumor effects.
Main Results:
- Trastuzumab is indicated for HER2-positive (IHC 3+ or FISH+) metastatic breast cancer, alone or with chemotherapy, prolonging survival.
- Cardiac toxicity associated with trastuzumab is distinct from anthracyclines and often reversible.
- Trastuzumab demonstrates a favorable safety and efficacy profile in metastatic disease.
Conclusions:
- The established efficacy and safety of trastuzumab in metastatic breast cancer support its investigation in the adjuvant setting.
- Widespread testing for HER2 overexpression facilitates targeted therapy with trastuzumab.
- Trastuzumab represents a significant advancement in HER2-positive breast cancer treatment.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:29Therapeutic Drug Monitoring: Affecting Factors